{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:28:55Z","timestamp":1781270935050,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1053\/j.ajkd.2011.06.027","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T02:14:15Z","timestamp":1314843255000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial"],"prefix":"10.1053","volume":"59","clinical-trial-number":[{"clinical-trial-number":"nct00958451","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Csaba P.","family":"Kovesdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun L.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Malakauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Andress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2011.06.027_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib3","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib5","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/ki.2010.189","article-title":"Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals","author":"Kalantar-Zadeh","year":"2010","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2011.06.027_bib6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11255-008-9346-7","article-title":"Bone and mineral disorders in pre-dialysis CKD","volume":"40","author":"Kovesdy","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJM197205182862009","article-title":"On the pathogenesis of the uremic state","volume":"286","author":"Bricker","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2011.06.027_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1210\/jcem-61-4-601","article-title":"On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency","volume":"61","author":"Llach","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2011.06.027_bib10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem-67-5-876","article-title":"Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure","volume":"67","author":"Pitts","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2011.06.027_bib11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1172\/JCI114022","article-title":"Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D","volume":"83","author":"Delmez","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2011.06.027_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/archinternmed.2008.604","article-title":"Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004","volume":"169","author":"Ginde","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ajkd.2011.06.027_bib13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jcem-67-4-644","article-title":"The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects","volume":"67","author":"Lips","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2011.06.027_bib15","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/ki.1982.70","article-title":"Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency","volume":"21","author":"Portale","year":"1982","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2215\/CJN.03850907","article-title":"Battleground: chronic kidney disorders mineral and bone disease\u2013calcium obsession, vitamin D, and binder confusion","volume":"3","author":"Kovesdy","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2011.06.027_bib20","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1744-9987.2005.00296.x","article-title":"Maxacalcitol is a possible less phosphatemic vitamin D analog","volume":"9","author":"Kazama","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1053\/j.ajkd.2011.06.027_bib22","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/ki.2008.35","article-title":"Vitamin D receptor activation and survival in chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib23","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.2215\/CJN.02590310","article-title":"Survival benefits with vitamin D receptor activation: new insights since 2003","volume":"5","author":"Kovesdy","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib24","first-page":"13","article-title":"Vitamin D metabolism: new concepts and clinical implications","volume":"24","author":"Anderson","year":"2003","journal-title":"Clin Biochem Rev"},{"key":"10.1053\/j.ajkd.2011.06.027_bib25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2215\/CJN.02140309","article-title":"Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease","volume":"4","author":"Kalantar-Zadeh","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"Bone metabolism and disease in chronic kidney disease","volume":"42","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2011.06.027_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins","volume":"4","author":"Payne","year":"1973","journal-title":"Br Med J"},{"key":"10.1053\/j.ajkd.2011.06.027_bib28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJM198706183162504","article-title":"Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure","volume":"316","author":"Korkor","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2011.06.027_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib30","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/ki.2008.343","article-title":"Oral active vitamin D is associated with improved survival in hemodialysis patients","volume":"74","author":"Naves-Diaz","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib31","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01760408","article-title":"Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients","volume":"3","author":"Shinaberger","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","article-title":"Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population","volume":"19","author":"Shoji","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2011.06.027_bib33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2011.06.027_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib35","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.06.027_bib36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ndt\/gfn592","article-title":"The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study","volume":"24","author":"Tentori","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2011.06.027_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitamin D treatment and mortality in chronic kidney disease","volume":"168","author":"Kovesdy","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ajkd.2011.06.027_bib38","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1681\/ASN.2007111164","article-title":"Association of oral calcitriol with improved survival in nondialyzed CKD","volume":"19","author":"Shoben","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.03940510","article-title":"Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"6","author":"Kandula","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-148-12-200806170-00013","article-title":"Vitamin D compounds in chronic kidney disease","volume":"148","author":"Coyne","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2011.06.027_bib41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2011.06.027_bib42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.07131009","article-title":"A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease","volume":"5","author":"Moe","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib43","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/ndt\/gfq144","article-title":"Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD","volume":"25","author":"Kovesdy","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2011.06.027_bib44","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1681\/ASN.2008010014","article-title":"Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients","volume":"19","author":"Regidor","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.06.027_bib45","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2011.06.027_bib46","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638611011395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638611011395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:59:03Z","timestamp":1759456743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638611011395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0272638611011395"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2011.06.027","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2011.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}